Stockscreener 앱 받기
106.60
0.48%
0.51
시간 외 거래:
106.60
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) On TRANSCEND And New Approvals, Buying Opportunity Or Priced In? - Sahm
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - Yahoo Finance UK
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151 - Moomoo
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - Ad-hoc-news.de
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 22% Upside Potential - DirectorsTalk Interviews
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with Promising Upside and Strong Buy Ratings - DirectorsTalk Interviews
Rhythm Pharmaceuticals Stock Rockets 28% With 11-Day Winning Streak - Trefis
(RYTM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak - Trefis
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director JEAN CHRISTOPHE - Moomoo
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MCGIRR DAVID W J - Moomoo
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Arbuckle Stuart A - Moomoo
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GOOD JENNIFER L - Moomoo
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals | 8-K: Current report - Moomoo
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
RYTM Forecast — Price Target — Prediction for 2027 - TradingView
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for SetmelanotideWhat's Changed - Sahm
Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director TETRAULT LYNN A. - Moomoo
8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm
Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union
Form 144 | Rhythm Pharmaceuticals(RYTM.US) Director Proposes to Sell 3.58 Million in Common Stocks - Moomoo
0.80%
2.11%
자본화:
|
볼륨(24시간):